var data={"title":"Cisapride (United States: Available via limited access/FDA investigational drug [IND] protocol only): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cisapride (United States: Available via limited access/FDA investigational drug [IND] protocol only): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5909?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">see &quot;Cisapride (United States: Available via limited access/FDA investigational drug [IND] protocol only): Drug information&quot;</a> and <a href=\"topic.htm?path=cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cisapride (United States: Available via limited access/FDA investigational drug [IND] protocol only): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708667\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Arrhythmias: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation, torsades de pointes, and QT prolongation have been reported in patients taking cisapride. From July 1993 through May 1999, more than 270 such cases have been spontaneously reported, including 70 fatalities. In approximately 85% of these cases the events occurred when cisapride was used in patients with known risk factors. These risk factors included the administration of other drugs which caused QT prolongation, inhibited the cytochrome P450 3A4 enzymes that metabolize cisapride, or depleted serum electrolytes; or the presence of disorders that may have predisposed patients to arrhythmias. In approximately 0.7% of these cases, the events occurred in the absence of identified risk factors; in the remaining cases, risk factor status was unknown. Because the cases were reported voluntarily from a population of unknown size, estimates of adverse event frequency cannot be made. </p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Numerous drug classes and agents increase the risk of developing serious cardiac arrhythmias. Cisapride is contraindicated in patients taking certain macrolide antibiotics (such as clarithromycin, erythromycin, and troleandromycin), certain antifungals (such as fluconazole, itraconazole, and ketoconazole), protease inhibitors (such as indinavir and ritonavir), phenothiazines (such as prochlorperazine and promethazine), Class IA and Class III antiarrhythmics (such as quinidine, procainamide, and sotalol); tricyclic antidepressants (such as amitriptyline); certain antidepressants (such as nefazodone and maprotiline); certain antipsychotic medications (such as sertindole), as well as other agents (such as bepridil, sparfloxacin, and grapefruit juice). The preceding list is not comprehensive.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">QT prolongation, torsades de pointes (sometimes with syncope), cardiac arrest and sudden death have been reported in patients taking cisapride without the above-mentioned contraindicated drugs. Most patients had disorders that may have predisposed them to arrhythmias with cisapride. These include history of prolonged electrocardiographic QT intervals or known family histroy of congenital long QT syndrome; history of ventricular arrhythmias, ischemic or valvular heart disease; other structural heart defects; cardiomyopathy; congestive heart failure; clinically significant bradycardia; sinus node dysfunction; second or third degree atrioventricular block; respiratory failure; or conditions that result in electrolyte disorders (hypokalemia, hypocalcemia, and hypomagnesemia), such as severe dehydration, vomiting, or malnutrition; eating disorders; renal failure; or the administration of potassium-wasting diuretics or insulin in acute settings. Cisapride is contraindicated in patients with these conditions. </p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">A 12-lead ECG should be performed prior to administration of cisapride. Treatment with cisapride should not be initiated if the QTc value exceeds 450 milliseconds. Serum electolytes (potassium, calcium and magnesium) and creatinine should be assessed prior to administration of cisapride and whenever conditions develop that may affect electrolyte balance or renal function. </p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">If syncope, rapid or irregular heartbeat develop, patients should immediately stop taking cisapride and seek the attention of a physician. </p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Recommended doses of cisapride should not be exceeded. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152071\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Propulsid&reg;</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057373\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Gastrointestinal Agent, Prokinetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442267\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>GERD/gastrointestinal dysmotility</b>: Very limited data available, efficacy results variable: PMA &ge;28 weeks: Oral: 0.1 to 0.2 mg/kg/dose 3 to 4 times/day; maximum daily dose: 0.8 mg/kg/day (Ariagno 2001; Deorari 1999; Enriquez 1998)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057367\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">see &quot;Cisapride (United States: Available via limited access/FDA investigational drug [IND] protocol only): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Pediatric: <b>GERD/gastrointestinal dysmotility: </b>Limited data available: Infants, Children, and Adolescents: Oral: 0.15 to 0.2 mg/kg/dose 3 to 4 times/day; maximum dose: 10 mg/dose. <b>Note:</b> Doses up to 0.3 mg/kg/dose every 8 hours have been described; however, due to safety concerns, most experts recommend a maximum dose of 0.8 mg/kg/day in divided doses (Shulman 1999; Vandenplas 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b> GERD/gastrointestinal dysmotility:</b> Oral: Initial: 10 mg 4 times/day at least 15 minutes before meals and at bedtime; in some patients the dosage will need to be increased to 20 mg to obtain a satisfactory result</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment</b>: There are no dosage adjustments provided in manufacturer&rsquo;s labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment</b>: Adults: Reduce daily dosage by 50%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152042\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11217380\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">In U.S., available via limited-access protocol only. Call  877-795-4247 for more information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8104790\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088994.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlzVeK77T+pk6YxDcA/z/ALg==&amp;TOPIC_ID=13159\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088994.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057376\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer &ge;15 minutes before meals or feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057375\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of nocturnal symptoms of gastroesophageal reflux disease (GERD), also demonstrated effectiveness for gastroparesis, refractory constipation, and nonulcer dyspepsia in adult patients failing other therapies</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152124\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Propulsid&reg; may be confused with propranolol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152123\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, drowsiness, extrapyramidal reaction, fatigue, headache, insomnia, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, diarrhea, dyspepsia, flatulence, nausea, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Aplastic anemia, granulocytopenia, leukopenia, pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Viral infection (increased incidence)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, rhinitis, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Apnea, bronchospasm, gynecomastia, hyperprolactinemia, methemoglobinemia, psychiatric disturbance, skin photosensitivity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152059\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity to cisapride or any component of the formulations; GI hemorrhage, mechanical obstruction, GI perforation, or other situations when GI motility stimulation is dangerous </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Serious cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation, torsade de pointes, and QT prolongation have been reported in patients taking cisapride with other drugs that inhibit CYP3A4. Some of these events have been fatal. Concomitant oral or intravenous administration of the following drugs with cisapride may lead to elevated cisapride blood levels and is contraindicated: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Antibiotics: Oral or IV erythromycin, clarithromycin, troleandomycin </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Antidepressants: Nefazodone </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Antifungals: Oral or IV fluconazole, itraconazole, miconazole, oral ketoconazole </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Protease inhibitors: Indinavir, ritonavir, amprenavir, atazanavir </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cisapride is also contraindicated for patients with a prolonged electrocardiographic QT intervals (QT<sub>c</sub> &gt;450 msec), a history of QT<sub>c</sub> prolongation, or known family history of congenital long QT syndrome; clinically significant bradycardia, renal failure, history of ventricular arrhythmias, ischemic heart disease, and congestive heart failure; uncorrected electrolyte disorders (hypokalemia, hypomagnesemia); respiratory failure; and concomitant medications known to prolong the QT interval and increase the risk of arrhythmia, such as certain antiarrhythmics, certain antipsychotics, certain antidepressants, bepridil, sparfloxacin, and terodiline. The preceding lists of drugs are not comprehensive. Cisapride should not be used in patients with uncorrected hypokalemia or hypomagnesemia or who might experience rapid reduction of plasma potassium such as those administered potassium-wasting diuretics and/or insulin in acute settings.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152046\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special note:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>On March 24, 2000, the FDA announced that the manufacturer of cisapride would voluntarily withdraw its product from the U.S. market on July 14, 2000. This decision was based on 341 reports of heart rhythm abnormalities including 80 reports of deaths. The company will continue to make the drug available to patients who meet specific clinical eligibility criteria for a limited-access protocol (contact 1-800-JANSSEN).</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmias: <b>[U.S. Boxed Warning]: Serious cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation, torsade de pointes, and QT prolongation have been reported in patients taking this drug.</b> Many of these patients also took drugs expected to increase cisapride blood levels by inhibiting the cytochrome P450 3A4 enzymes that metabolize cisapride. These drugs include clarithromycin, erythromycin, troleandomycin, nefazodone, fluconazole, itraconazole, ketoconazole, indinavir and ritonavir. Some of these events have been fatal. Cisapride is contraindicated in patients taking any of these drugs. <b>QT prolongation, torsade de pointes (sometimes with syncope), cardiac arrest and sudden death have been reported in patients taking cisapride without the above-mentioned contraindicated drugs.</b> Most patients had disorders that may have predisposed them to arrhythmias with cisapride. Cisapride is contraindicated for those patients with: history of prolonged electrocardiographic QT intervals; renal failure; history of ventricular arrhythmias, ischemic heart disease, and HF; uncorrected electrolyte disorders (hypokalemia, hypomagnesemia); respiratory failure; and concomitant medications known to prolong the QT interval and increase the risk of arrhythmia, such as certain antiarrhythmics, including those of Class Ia (such as quinidine and procainamide) and Class III (such as sotalol); tricyclic antidepressants (such as amitriptyline); certain tetracyclic antidepressants (such as maprotiline); certain antipsychotic medications (such as certain phenothiazines and sertindole), protease inhibitors, bepridil, sparfloxacin and terodiline. (The preceding lists of drugs are not comprehensive.) Recommended doses of cisapride should not be exceeded. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Electrolyte disturbances: Should not be used in patients with uncorrected hypokalemia or hypomagnesemia, such as those with severe dehydration, vomiting or malnutrition, or those taking potassium-wasting diuretics; should also not be used in patients who might experience rapid reduction of plasma potassium, such as those administered potassium-wasting diuretics and/or insulin in acute settings. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Risk vs. benefit: Potential benefits should be weighed against risks prior administration of cisapride to patients who have or may develop prolongation of cardiac conduction intervals, particularly QT<sub>c</sub>. These include patients with conditions that could predispose them to the development of serious arrhythmias, such as multiple organ failure, COPD, apnea and advanced cancer. Patients should have a baseline ECG and an electrolyte panel (magnesium, calcium, potassium) prior to initiating cisapride (see Contraindications). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152114\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152050\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13159&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Cisapride may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, Alcohol (Ethyl) sedative and psychomotor effects may be enhanced.  Alcohol (Ethyl) may also worsen nocturnal heartburn. Cisapride may increase the serum concentration of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amitriptyline: May enhance the arrhythmogenic effect of Cisapride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May increase the serum concentration of Cisapride. Isavuconazonium considerations are addressed in separate monographs.<b> Exceptions: </b>Isavuconazonium Sulfate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Cisapride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of Cisapride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bepridil: Cisapride may enhance the QTc-prolonging effect of Bepridil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bicalutamide: May increase the serum concentration of Cisapride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Cisapride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Cisapride. Management: Consider alternatives to cimetidine. If this combination cannot be avoided, monitor for toxic effects of cisapride if cimetidine is initiated/dose increased, or decreased efficacy if cimetidine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Cisapride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of Cisapride. The active metabolite aprepitant is likely responsible for this effect.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Cisapride. Management: Minimize consumption of grapefruit/grapefruit juice during cisapride therapy. Monitor for toxic effects of cisapride (eg, QT interval prolongation, ventricular arrhythmia) if grapefruit/grapefruit juice is added/increased in the diet.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loprazolam: Cisapride may enhance the therapeutic effect of Loprazolam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May enhance the QTc-prolonging effect of Cisapride. Macrolide Antibiotics may decrease the metabolism of Cisapride.<b> Exceptions: </b>Fidaxomicin; Spiramycin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nefazodone: May increase the serum concentration of Cisapride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: Cisapride may increase the serum concentration of NIFEdipine. Reported with sustained release nifedipine product. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protriptyline: May enhance the arrhythmogenic effect of Cisapride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of Cisapride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Cisapride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152068\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Coadministration of grapefruit juice with cisapride increases the bioavailability of cisapride. Management: Avoid consumption of grapefruit/grapefruit juice during cisapride therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152051\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10912627\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057372\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ECG (prior to beginning therapy and periodically during therapy), serum electrolytes (potassium, calcium, magnesium) and creatinine should be assessed prior to initiation and whenever conditions develop that may affect electrolyte balance or renal function (eg, dehydration, vomiting)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152045\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Enhances the release of acetylcholine at the myenteric plexus. <i>In vitro</i> studies have shown cisapride to have serotonin-4 receptor agonistic properties which may increase gastrointestinal motility and cardiac rate; increases lower esophageal sphincter pressure and lower esophageal peristalsis; accelerates gastric emptying of both liquids and solids.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152058\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 0.5-1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 97.5% to 98% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensive in liver via cytochrome P450 isoenzyme CYP 3A3/4 to norcisapride</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 35% to 40% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 6-12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine and feces (&lt;10%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152061\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acpulsif (ID);</li>\n      <li>Alimix (GR);</li>\n      <li>Cisamod (VE);</li>\n      <li>Cisaride (TH);</li>\n      <li>Gasprid (PL);</li>\n      <li>Gastromet (CL);</li>\n      <li>Ondax (CL);</li>\n      <li>Peptax (UY);</li>\n      <li>Prepulsid (CN, VN, ZA);</li>\n      <li>Pridesia (ID);</li>\n      <li>Stimulit (ID);</li>\n      <li>Unamol (CR, DO, GT, HN, MX, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ariagno RL, Kikkert MA, Mirmiran M, Conrad C, Baldwin RB. Cisapride decreases gastroesophageal reflux in preterm infants. <i>Pediatrics</i>. 2001;107(4):E58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/1335779/pubmed\" target=\"_blank\" id=\"1335779\">1335779</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cucchiara S, Staiano A, Boccieri A, et al, &ldquo;Effects of Cisapride on Parameters of Oesophageal Motility and on the Prolonged Intraoesophageal pH Test in Infants With Gastro-Oesophageal Reflux Disease,&rdquo; <i>Gut</i>, 1990, 31(1):21-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/2180792/pubmed\" target=\"_blank\" id=\"2180792\">2180792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deorari AK, Reddy PS, Paul VK, Bal CS. Randomised controlled trial of cisapride in preterm neonates for gastric emptying time. <i>Arch Dis Child Fetal Neonatal Ed</i>. 1999;81(2):F159.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/10507879/pubmed\" target=\"_blank\" id=\"10507879\">10507879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Enriquez A, Bolisetty S, Patole S, Garvey PA, Campbell PJ. Randomised controlled trial of cisapride in feed intolerance in preterm infants. <i>Arch Dis Child Fetal Neonatal Ed</i>. 1998;79(2):F110-113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/9828736/pubmed\" target=\"_blank\" id=\"9828736\">9828736</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill SL, Evangelista KJ, Pizzi AM, et al, &ldquo;Proarrhythmia Associated With Cisapride in Children,&rdquo; <i>Pediatrics</i>, 1998, 101(6):1053-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/9606235 /pubmed\" target=\"_blank\" id=\"9606235 \">9606235 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hofmeyr GJ and Sonnendecker EW, &quot;Secretion of the Gastrokinetic Agent Cisapride in Human Milk,&quot; <i>Eur J Clin Pharmacol</i>, 1986, 30(6):735-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/3770067/pubmed\" target=\"_blank\" id=\"3770067\">3770067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Janssens G, Melis K, Vaerenberg M. Long-term use of cisapride (prepulsid) in premature neonates of less than 34 weeks gestational age. <i>J Pediatr Gastroenterol Nutr</i>. 1990;11(3):420-422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/2246729/pubmed\" target=\"_blank\" id=\"2246729\">2246729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khongphatthanayothin A, Lane J, Thomas D, et al, &ldquo;Effects of Cisapride on QT Interval in Children,&rdquo; <i>J Pediatr</i>, 1998, 133(1):51-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/9672510/pubmed\" target=\"_blank\" id=\"9672510\">9672510</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lander A, &ldquo;The Risks and Benefits of Cisapride in Premature Neonates, Infants and Children,&rdquo; <i>Arch Dis Child</i>, 1998, 79:469-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/10210987/pubmed\" target=\"_blank\" id=\"10210987\">10210987</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewin MB, Bryant RM, Fenrich AL, et al, &ldquo;Cisapride-Induced QT Interval,&rdquo; <i>J Pediatr</i>, 1996, 128(2):279-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/8636830/pubmed\" target=\"_blank\" id=\"8636830\">8636830</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Propulsid (cisapride) [prescribing information]. Titusville, NJ: Janssen Pharmaceutica; January 2000.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/8636830/pubmed\" target=\"_blank\" id=\"8636830\">8636830</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman RJ, Boyle JT, Colletti RB, et al. The use of cisapride in children. The North American Society for Pediatric Gastroenterology and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 1999;28(5):529-533.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/10328132/pubmed\" target=\"_blank\" id=\"10328132\">10328132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vandenplas Y; ESPGHAN Cisapride Panel. European Society for Pediatric Gastroenterology, Hepatology and Nutrition. Current pediatric indications for cisapride. <i>J Pediatr Gastroenterol Nutr</i>. 2000;31(5):480-489.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/11144431/pubmed\" target=\"_blank\" id=\"11144431\">11144431</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Eygen M and Van Ravensteyn H, &ldquo;Effect of Cisapride on Excessive Regurgitation in Infants,&rdquo; <i>Clin Ther</i>, 1989, 11(5):669-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/2805024 /pubmed\" target=\"_blank\" id=\"2805024 \">2805024 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13159 Version 108.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708667\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F152071\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057373\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442267\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1057367\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F152042\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11217380\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F8104790\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057376\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057375\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F152124\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F152123\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F152059\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F152046\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F152114\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F152050\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F152068\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F152051\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10912627\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1057372\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F152045\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F152058\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F152061\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13159|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Cisapride (United States: Available via limited access/FDA investigational drug [IND] protocol only): Drug information</a></li><li><a href=\"topic.htm?path=cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">Cisapride (United States: Available via limited access/FDA investigational drug [IND] protocol only): Patient drug information</a></li></ul></div></div>","javascript":null}